氨力农对失代偿期肺心病的疗效及安全性

Effect and safety of amrinone on the respiratory and cardiac function in patients with uncompensated chronic cor pulmonale.

目的 了解氨力农对慢性肺心病肺心功能失代偿期患者的肺心功能的影响及安全性。方法 肺心病肺心功能失代偿期患者随机分两组 :氨力农组 32例 ,在常规利尿、扩血管治疗的基础上加用氨力农 15 0mg ;洋地黄组 32例 ,常规进行强心利尿、扩血管治疗 ,疗程 7天。观察治疗前后的心功能的改善情况 ,超声心动图检测肺动脉压力和射血分数及肺功能仪测定肺活量、残气量 /肺总量、一秒用力肺活量值 ,并记录不良反应。结果 氨力农组心功能改善总有效 2 7例 (84 .4 % ) ;洋地黄组心功能改善总有效 2 8例 (87.5 % ) ;用药前后的肺动脉压力、射血分数、肺活量等均有显著改善 (P <0 .0 5 ) ,各指标二组对照无明显差异 (P >0 .0 5 )。氨力农组不良反应发生率为 0。

Objective To evaluate the effect and safety of amrinone on the respiratory and cardiac function in patients with uncompensated chronic cor pulmonale.Methods 64 inpatients with uncompensated cor pulmonale were randomized to the amrinone group and the digitalis group. In the amrinone group, patients were prescribed intravenous amrinone 150 mg at the rate. Patients in the digitalis group received routine treatments for seven days.We observed the changes of cardiac function, pulmonary artery pressure, ejection fraction, vital capacity (VC), RV/TLC and FEV1 before and after treatment. Adverse reactions were also recorded.Results In the amrinone group, the total efficiency of 84.4%, while in the digitalis group, the total efficiency of 87.5%. Furthermore, pulmonary artery pressure, ejection fraction, VC, RV/TLC and FEV 1 after treatment were greatly improved. All these measurements had no difference in two groups. The frequency of adverse reactions was 0 and 12.5%, respectively in the amrinone group and the digitalis group.Conclusion Amrinone is effective and safe for the treatment of uncompensated chronic cor pulmonale.